Results 61 to 70 of about 2,552 (169)

Safety, tolerability and risk benefit analysis of tiotropium in COPD

International Journal of COPD, 2008
Yuji Oba, Tareq Zaza, Danish M ThameemUniversity of Missouri, School of Medicine, Division of Pulmonary, Critical Care and Environmental Medicine, Columbia, MO, USAAbstract: COPD is a chronic disease and, like many other chronic diseases, there is no ...
Yuji Oba, Tareq Zaza, Danish M Thameem
doaj  

Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations

Therapeutics and Clinical Risk Management, 2016
Ching Kuo Tan, Gui Quan Say, James B Geake Department of Respiratory Medicine, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia Abstract: Tiotropium bromide is a long-acting inhaled muscarinic antagonist used in patients with chronic respiratory ...
Tan CK, Say GQ, Geake JB
doaj  

Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice

Медицинский совет, 2019
Today, chronic obstructive pulmonary disease is the fourth global cause of deaths worldwide. A number of studies showed that 11 to 16 million people might suffer from the chronic obstructive pulmonary disease in Russia.
Р. A. Balunov, A. N. Khitrov
doaj   +1 more source

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England. [PDF]

Int J Chron Obstruct Pulmon Dis, 2023
Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.   +12 more
europepmc   +1 more source

Efficacy and safety of carvedilol in combination with bronchodilators in patients with CHF of ischemic origin and COPD.

Клиническая практика, 2019
Objective. To study the effectiveness of carvedilol, tiotropium bromide and indacaterol in complex therapy on clinical and functional parameters in patients with CHF of ischemic origin in combination with COPD. Material and methods. The study included
Vladimir V. Evdokimov, A. G. Evdokimova, E. N. Yushchuk   +2 more
doaj   +1 more source

Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease. [PDF]

Comput Math Methods Med, 2021
Yu S, Zhang C, Yan Z, Fang Q, Gao X.
europepmc   +1 more source

1H-NMR-based metabolic profiling of healthy individuals and high-resolution CT-classified phenotypes of COPD with treatment of tiotropium bromide

International Journal of COPD, 2018
Li-Chuan Tan,1 Wen-Jie Yang,2 Wei-Ping Fu,1 Ping Su,2 Jing-Kui Shu,1 Lu-Ming Dai1 1Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Kunming Medical University, Kunming 650032, People’s Republic of China ...
Tan LC, Yang WJ, Fu WP, Su P, Shu JK, Dai LM   +5 more
doaj  

Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol. [PDF]

J Manag Care Spec Pharm, 2023
Sethi S, Palli SR, Bengtson LGS, Buysman EK, Clark B, Sargent A, Shaikh A, Ferguson GT.   +7 more
europepmc   +1 more source

Efficacy of tiotropium in the prevention of exacerbations of COPD

Therapeutic Advances in Respiratory Disease, 2009
Exacerbations are the most frequent cause of medical visits, hospital admissions and death among patients with chronic obstructive pulmonary disease (COPD).
Antonio Anzueto, Marc Miravitlles
doaj   +1 more source

Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History. [PDF]

Int J Chron Obstruct Pulmon Dis, 2023
Sethi S, Clark B, Bengtson LGS, Buysman EK, Palli S, Sargent A, Shaikh A, Ferguson GT.   +7 more
europepmc   +1 more source